export default function Ara290OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        ARA-290 is a research peptide derived from a specific region of erythropoietin — the hormone known for stimulating red blood cell production — but designed to avoid that blood-building effect entirely. Instead, it targets a separate receptor system that promotes nerve survival and dampens inflammation. Small clinical trials in neuropathic pain have shown promising results. It is not an approved drug and not commercially available as a pharmaceutical.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Person With Chronic Pain or Nerve Damage — Looking for something that might address neuropathic symptoms</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have neuropathy — burning, tingling, numbness in my feet — and nothing I&rsquo;ve tried really helps. I heard there&rsquo;s a research peptide that might repair nerves. Is this real, and is there any actual evidence?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Small trials actually showed nerve repair, not just pain relief</strong><br />In a study of patients with sarcoidosis-associated small fiber neuropathy, ARA-290 didn&rsquo;t just reduce pain scores — it was associated with an increase in intraepidermal nerve fiber density, which is a direct structural measure of nerve tissue. That is a qualitatively different kind of result than a painkiller. If the findings hold up, it suggests the compound might be promoting actual nerve repair rather than just masking symptoms.</li>
          <li><strong>It targets inflammation and nerve survival together</strong><br />Neuropathic conditions often involve both damaged nerves and ongoing local inflammation that prevents healing. ARA-290&rsquo;s proposed mechanism addresses both: it supports the survival of nerve cells and dampens inflammatory signals. For someone whose neuropathy involves an inflammatory component — which sarcoidosis and diabetic neuropathy both do — that dual mechanism is conceptually relevant.</li>
          <li><strong>It avoids the blood-thickening risk associated with EPO</strong><br />Erythropoietin is a banned performance-enhancing substance because it increases red blood cells, thickening the blood and raising clotting risk. ARA-290 is specifically designed to not activate that pathway. The receptor it targets does not drive red blood cell production, which removes the most significant safety concern associated with EPO-derived compounds.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The evidence base is small trials — we are talking about studies with dozens of patients, not hundreds or thousands. The nerve fiber density finding in the sarcoidosis study is genuinely exciting but has not been replicated in a large controlled trial. ARA-290 is not an approved drug, is not available as a pharmaceutical, and is sourced from research chemical vendors with no manufacturing standards or verified purity. There is no established dosing protocol, no approved safety monitoring framework, and no regulatory oversight for use outside of clinical trials. The neuropathic pain conditions it was studied for also have limited treatment options, which makes it understandable that people seek alternatives — but the distance between &ldquo;promising small trial&rdquo; and &ldquo;established effective treatment&rdquo; is large. Net: genuine biological plausibility and some encouraging preliminary data — but not yet a proven treatment, and sourcing outside of a clinical trial means meaningful unknown risks.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Wellness-Curious Person — Interested in neuroprotection and anti-inflammatory compounds</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;m interested in compounds that protect the nervous system and reduce inflammation. If ARA-290 promotes nerve health without the red blood cell effects of EPO, is it something worth knowing about for longevity or brain health applications?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Nerve protection is a longevity-relevant target</strong><br />Age-related nerve decline — sensory loss, slower reflexes, reduced peripheral sensation — is a real and underappreciated aspect of aging. Compounds that support nerve survival and reduce inflammatory damage to the nervous system fit naturally into a longevity-oriented framework. ARA-290&rsquo;s mechanism targets exactly this kind of nerve maintenance pathway.</li>
          <li><strong>The anti-inflammatory effect is systemic and not tissue-specific</strong><br />ARA-290&rsquo;s target receptor is expressed broadly in non-nervous system tissues as well — heart, kidney, retina. The protective and anti-inflammatory effects, if they generalize, would represent a broad tissue-protective signal rather than just a peripheral nerve treatment. That systemic protective potential is appealing to anyone thinking about organ health across aging.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The clinical research conducted so far focused specifically on active disease states — sarcoidosis neuropathy and diabetic neuropathy — not on healthy people without those conditions. Extrapolating results from a disease population to healthy aging is a significant inferential leap. There are no studies of ARA-290 in healthy adults, no established longevity benefit, and no data on long-term use or what sustained receptor activation of this pathway does over years. The compound is a research chemical with no quality controls accessible outside of clinical trials. Net: the biological mechanism is genuinely interesting for aging biology, but applying results from diseased populations to healthy optimization use is speculation — and the research chemical sourcing problem is a real practical barrier to safe use regardless of the biology.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Research-Forward Biohacker — Interested in the EPO tissue-protection receptor system and its implications</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The innate repair receptor that ARA-290 targets is a heterodimer of the EPO receptor and the beta common receptor. What does the tissue distribution and downstream signaling of that receptor complex tell us about where ARA-290 would and wouldn&rsquo;t be expected to work — and what would confirm or deny the nerve regeneration finding from the sarcoidosis trial?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The receptor biology here is genuinely novel and underexplored</strong><br />The existence of a tissue-protective EPO receptor system — distinct from the blood-cell-producing one — was only characterized in the early 2000s. The heterodimeric receptor that ARA-290 targets is expressed in peripheral nerve, brain, retina, kidney, and heart, but not in the bone marrow cells that produce red blood cells. This receptor dissociation is what makes the pharmacological hypothesis possible and represents genuinely interesting receptor pharmacology that is still being worked out.</li>
          <li><strong>The intraepidermal nerve fiber density endpoint is methodologically important</strong><br />Using nerve fiber density as a structural outcome rather than just pain scores is methodologically sophisticated. Pain is subjective and susceptible to placebo; actual nerve fiber counts from skin punch biopsy are objective structural measurements. The fact that the sarcoidosis study showed an increase in this structural endpoint is what elevates it above typical small-trial pain research. It suggests a biological mechanism is operating, not just a subjective effect.</li>
          <li><strong>ARA-290 maps onto a broader question about erythropoietin&rsquo;s non-hematopoietic functions</strong><br />EPO&rsquo;s tissue-protective effects have been observed in rodent models of stroke, cardiac injury, and retinal degeneration. The challenge has been that full-length EPO also stimulates red blood cell production at doses needed for tissue protection — creating unacceptable safety risk for non-anemia applications. ARA-290 represents the most advanced attempt to clinically isolate the tissue-protection function. Whether it succeeds will say something meaningful about how separable those two functions actually are in humans.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The sarcoidosis SFN trial is the strongest evidence base but remains a small single study. Diabetic neuropathy trials were encouraging but underpowered for definitive conclusions. There is no Phase III confirmatory trial with the statistical power to confidently establish efficacy. The question of what the tissue-protective receptor pathway actually does in long-term sustained activation — as opposed to the acute signaling studied in trials — is genuinely unknown. The off-target risk profile is characterized only for short-term administration in trial populations, not for the extended use that community application implies. Net: an intellectually important compound for understanding EPO biology beyond hematopoiesis — but the clinical story is still early, and the gap between biological plausibility and proven human therapeutic effect remains large, particularly for use cases beyond the specific neuropathic conditions studied.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What ARA-290 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not an approved drug — no completed Phase III trials, no regulatory approval</li>
              <li>Not EPO — designed to avoid red blood cell stimulation entirely</li>
              <li>Not a proven treatment for neuropathy — promising preliminary data, not established efficacy</li>
              <li>Not available in pharmaceutical grade — research chemical supply only, no manufacturing QC</li>
              <li>Not studied in healthy people — all trials enrolled patients with specific disease states</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The nerve fiber density finding in the sarcoidosis trial is a structural outcome, not just a pain score — it suggests real biological activity</li>
              <li>The receptor system it targets is genuinely novel and undercharacterized in the literature</li>
              <li>Neuroprotection without red blood cell stimulation is a pharmacologically elegant separation of EPO&rsquo;s two distinct functions</li>
              <li>Addresses conditions — small fiber neuropathy, diabetic neuropathy — with very limited treatment options</li>
              <li>The mechanistic framework (tissue-protective EPO signaling) is broader than just this compound and has implications for multiple organ systems</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
